Skip to content
PIL Logo

Femoston-conti 0.5mg/2.5mg

Last Updated on eMC 30-Aug-2016 View document  | Mylan Products Limited Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 30-Aug-2016 and displayed until Current

Reasons for adding or updating:

  • Change to section 6 - marketing authorisation holder

Updated on 11-May-2016 and displayed until 30-Aug-2016

Reasons for adding or updating:

  • Change to section 2 - what you need to know - warnings and precautions

Updated on 06-Aug-2015 and displayed until 11-May-2016

Reasons for adding or updating:

  • Change to section 1 - what the product is
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 3 - how to take/use
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 13-Apr-2015 and displayed until 06-Aug-2015

Reasons for adding or updating:

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision
  • Company name change or merger

Updated on 26-Mar-2015 and displayed until 13-Apr-2015

Reasons for adding or updating:

  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - use in children/adolescents
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects

Updated on 28-Jul-2014 and displayed until 26-Mar-2015

Reasons for adding or updating:

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 03-Jan-2013 and displayed until 28-Jul-2014

Reasons for adding or updating:

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 11-Oct-2012 and displayed until 03-Jan-2013

Reasons for adding or updating:

  • New PIL for eMC ie a PIL for an existing product but one that is new to the eMC

Company contact details

Mylan Products Limited

Company image
Address

20 Station Close, Potters Bar, Hertfordshire, EN6 1TL, UK

Medical Information Direct Line

+44 (0)1707 853000

Telephone

+44 (0)1707 853 000

Medical Information e-mail

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

dydrogesterone, estradiol hemihydrate

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue